AHFS Injectable Drug Information November 2023 Update

This update contains 11 new monographs, and 35 revised monographs

New monographs: Ciltacabtagene Autoleucel; Delandistrogene Moxeparvovec-rokl; Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate; Lisocabtagene Maraleucel; Momelotinib Dihydrochloride; Motixafortide Acetate; Nadofaragene Firadenovec-vncg; Palovarotene; Pozelimab-bbfg; Tisagenlecleucel; Umeclidinium Bromide and Vilanterol Trifenatate.

Revised monographs:  Anifrolumab-fnia; Antihemophilic Factor (Recombinant), Fc fusion protein; Apremilast; Bempedoic Acid; Bupropion; Cabotegravir; Cephalosporins General Statement; Cladribine; Clascoterone; Crizanlizumab-tmca; Darolutamide; Dasatinib; Dimethyl Fumarate; Diroximel Fumarate; Efgartigimod Alfa-fcab; Emicizumab-kxwh; Fedratinib Hydrochloride ; Fluticasone Furoate and Vilanterol Trifenatate; Inclisiran Sodium; Ixazomib Citrate; Lenacapavir Sodium; Methoxy Polyethylene Glycol-epoetin Beta; Nilotinib; Osimertinib Mesylate; Peginterferon Beta-1a; PONATinib; Remdesivir; Respiratory Syncytial Virus Vaccine; Respiratory Syncytial Virus Vaccine, Adjuvanted; rifAXIMin; Selpercatinib; Sotorasib; Tirbanibulin; traMADol Hydrochloride; Tucatinib.